[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Suncadia Pharmaceuticals Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":191},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,42,61,86,105,127,149,171],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100624047","phase-2-a-study-of-shr-1918-in-participants-with-hypercholesterolemia-with-inadequate-lipid-control-on-statins-plus-pcsk9-inhibitors-100624047",false,"NCT07404553","A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II\u002FIII Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors","Inclusion Criteria:\n\n1. Male and female ≥ 18 years old and ≤ 85 years old, who is able and willing to provide a written informed consent.\n2. TG ≤ 5.6 mmol\u002FL.\n3. LDL-C ≥ 2.6 mmol\u002FL for moderate to high ASCVD risk, LDL-C ≥ 1.8 mmol\u002FL for very high ASCVD risk, LDL-C ≥ 1.4 mmol\u002FL for ultra-high ASCVD risk.\n4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol.\n\nExclusion Criteria:\n\n1. History of severe allergies\u002Fhypersensitivity reactions, or clinically significant allergies\u002Fhypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures.\n2. Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization.\n3. Acute ischemic ASCVD events within 3 months prior to screening or randomization.\n4. Have severe cardiac arrhythmia within 3 months prior to screening or randomization.\n5. Echocardiography indicates a left ventricular ejection fraction (LVEF) of less than 30% within 3 months prior to screening.\n6. History of percutaneous coronary intervention, history of coronary artery bypass grafting (CABG), history of peripheral arterial revascularisation within 1 month prior to screening or randomization.\n7. Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension.\n8. Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization.\n9. Malignant tumors within 5 years.\n10. It's planned to research transcutaneous coronary intervention, coronary artery bypass grafting, carotid or peripheral artery reconstruction, pacemaker implantation, cardiac resynchronisation therapy (CRT), implantable cardioverter defibrillator (ICD) implantation and other implantations during the study.\n11. Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening.\n12. Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period.\n13. History of drug use, substance abuse, and alcohol abuse.\n14. Participated in or is participating in other clinical studies and has received study interventions within the past month prior to screening.\n15. Researchers determine that the subject has poor compliance or any factors that make them unsuitable for participation in this trial, including but not limited to participation in the study placing the subject at unacceptable risk or potentially interfering with the study results.","ALL","18 Years","85 Years",{"count":20,"type":21},126,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.",[28],"Hypercholesterolemia","RECRUITING","2026-06-15",{"date":32,"type":33},"2026-06-16","ACTUAL",{"date":35,"type":33},"2026-04-30",{"date":37,"type":21},"2028-08",{"name":39,"class":40},"Beijing Suncadia Pharmaceuticals Co., Ltd","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":41},"100619822","phase-3-a-study-of-shr-1918-in-participants-with-hypertriglyceridemia-100619822","NCT07349615","A Study of SHR-1918 In Participants With Hypertriglyceridemia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypertriglyceridemia","Inclusion Criteria:\n\n1. Male and female ≥ 18 years old, who is able and willing to provide a written informed consent.\n2. 1.7 ≤ TG ≤ 5.6 mmol\u002FL.\n3. LDL-C \\\u003C 3.4 mmol\u002FL.\n4. Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol.\n\nExclusion Criteria:\n\n1. History of severe allergies\u002Fhypersensitivity reactions, or clinically significant allergies\u002Fhypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures.\n2. Received or are currently receiving treatment with monoclonal antibodies, siRNA-based drugs, or ASO-based drugs targeting the same target prior to screening.\n3. Have a history of pancreatitis prior to screening or randomization.\n4. Acute ischemic ASCVD events within 3 months prior to screening or randomization.\n5. Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization.\n6. Malignant tumors within 5 years.\n7. Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening.\n8. Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization.\n9. Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension.\n10. Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period.",{"count":50,"type":21},360,[25],"The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypertriglyceridemia. The efficacy and safety of SHR-1918 will be evaluated after 24-weeks and 48-weeks treatment.",[54],"Hypertriglyceridemia",{"date":32,"type":33},{"date":57,"type":33},"2026-04-01",{"date":59,"type":21},"2027-11",{"name":39,"class":40},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":41},"100614541","phase-1-a-study-of-shr-2906-injection-in-healthy-subjects-with-a-single-dose-and-in-obese-patients-with-multiple-doses-100614541","NCT07280936","A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses","A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form prior to any study-related activities, understand the procedures and methods of the study, and agree to complete this study in strict accordance with the clinical study protocol;\n2. Males or females aged 18-55 years (inclusive);\n3. Subjects who are generally healthy as judged by the investigator based on medical history, vital signs, physical examination, laboratory tests, and electrocardiogram (ECG);\n4. At screening, 19.0 ≤ BMI ≤ 23.9 kg\u002Fm2 (inclusive) for Part I or 28.0 ≤ BMI ≤ 35.0 kg\u002Fm2 (inclusive) for Part II.\n\nExclusion Criteria:\n\n1. During screening, electrocardiogram (ECG) indicated that QTcF\\>450 ms in males and QTcF\\> 470 ms in females, as well as other abnormal ECG and vital signs that were judged by the researchers to have clinical significance;\n2. There are endocrine diseases or medical histories that may significantly affect body weight during screening (such as Cushing's syndrome, diabetes, hypothyroidism or hyperthyroidism, etc.);\n3. There is a history or family history of medullary thyroid carcinoma, multiple endocrine adenomatosis type 2, or a history of pancreatitis or symptomatic gallbladder disease;\n4. Other clinical findings within 12 months prior to screening that show clinical significance in the following diseases (including but not limited to gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases);\n5. Use of prescription drugs (excluding topical eye\u002Fnasal drops and creams without systemic exposure risk), over-the-counter drugs, food supplements, vitamins and Chinese herbal medicines (excluding conventional vitamins) within two weeks prior to screening;\n6. Having undergone gastrointestinal surgery that may cause malabsorption before screening, or having taken drugs that directly affect gastrointestinal peristalsis for a long time. For example: having undergone bariatric surgery or procedures (such as gastric banding), or having used weight-reducing drugs (including but not limited to orlistat) within 3 months before administration, or having a weight change of more than 10% within 3 months before administration;\n7. Those who have a history of drug abuse in the past five years or have used drugs in the three months prior to the trial; Or the urine drug screening is positive;\n8. Blood donation of ≥200 mL within one month prior to screening; Or those who have donated ≥400 mL of blood or lost ≥400 mL of blood within 3 months prior to screening due to trauma or major surgical operations;\n9. Inability to tolerate venipuncture for blood collection or fainting at the sight of needles and blood;\n10. There are special dietary requirements and they cannot follow the uniform diet;\n11. Subjects who the researchers consider to have other factors that make them unsuitable for participating in this trial.",true,"55 Years",{"count":71,"type":21},124,[73],"PHASE1","This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation study (MAD) in obese patients.",[76,77],"Obesity","Overweight","2026-05-12",{"date":80,"type":33},"2026-05-14",{"date":82,"type":33},"2026-01-05",{"date":84,"type":21},"2026-12",{"name":39,"class":40},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":41},"100610680","phase-3-a-trial-to-evaluate-the-efficacy-and-safety-of-shr-1918-in-patients-with-hyperlipidemia-100610680","NCT07230730","A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia","Inclusion Criteria:\n\n1. the age must be at least 18 years old, and both men and women are eligible;\n2. the patient was receiving a stable dose of statins at the time of screening,, and the fasting LDL-C met: For individuals with extremely high risk of ASCVD, LDL-C≥1.4 mmol\u002FL; for those with very high risk of ASCVD, LDL-C≥1.8 mmol\u002FL; and for those with medium and high risk of ASCVD, ≥2.6 mol\u002FL;\n3. Fasting TG≥ 1.7 mmol\u002FL;\n4. Understand the research procedures and methods, voluntarily participate in this trial and sign the informed consent form in person；\n\nExclusion Criteria:\n\n1. poorly controlled hypertension (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg) at the time of screening or before randomization；\n2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or γ -glutamyl transferase (GGT) \\> 3× upper limit of normal (ULN), or total bilirubin \\> 2×ULN；\n3. Thyroid stimulating hormone (TSH) is lower than the lower limit of normal (LLN) or greater than 1.5×ULN；\n4. The estimated glomerular filtration rate (eGFR) is less than 30 mL\u002Fmin\u002F1.73m2；\n5. Previously suffering from diseases that have a significant impact on blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, etc",{"count":94,"type":21},900,[25],"The study is being conducted to evaluate the efficacy, and safety of SHR-1918 in reducing serum low-density lipoprotein cholesterol (LDL-C) and total triglycerides (TG) in patients with hyperlipidemia compared with placebo, and also includes To evaluate the effectiveness of SHR-1918 in reducing other lipid indicators in patients with mixed hyperlipidemia and to assess the safety of SHR-1918 in patients with mixed hyperlipidemia.",[98],"Hyperlipidemia",{"date":80,"type":33},{"date":101,"type":33},"2026-01-13",{"date":103,"type":21},"2027-10",{"name":39,"class":40},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":68,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":41},"100610635","phase-1-a-trial-of-shr-4658-in-healthy-volunteers-or-volunteers-with-elevated-blood-pressure-100610635","NCT07230145","A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure","A Double-Blind, Randomized, Dose-Escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent.\n2. Blood pressure as defined in the protocol.\n3. Male or female，aged 18 to 55 years (inclusive).\n4. Meet the weight standard.\n\nExclusion Criteria:\n\n1. Known history or current clinically significant disease.\n2. Protocol-defined risk factors for disease.\n3. Participated in clinical trials of other drugs or medical devices.\n4. Pregnant or nursing women.",{"count":113,"type":21},48,[73],"This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of single subcutaneous injection of SHR-4658 in healthy volunteers and volunteers with elevated blood pressure.",[117],"Heart Failure","NOT_YET_RECRUITING","2025-11-13",{"date":121,"type":33},"2025-11-17",{"date":123,"type":21},"2025-11",{"date":125,"type":21},"2026-07",{"name":39,"class":40},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":41},"100572390","phase-2-the-efficacy-and-safety-of-hrs8179-in-severe-cerebral-edema-following-large-hemispheric-infarction-100572390","NCT06732648","The Efficacy and Safety of HRS8179 in Severe Cerebral Edema Following Large Hemispheric Infarction","The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II\u002FIII Clinical Trial","Inclusion Criteria:\n\n1. Fully understand and voluntarily participate in this trial, and sign the informed consent form (the informed consent form can be signed voluntarily by the participant or their legal representative);\n2. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory;\n3. National Institutes of Health Stroke Scale (NIHSS) ≥ 10 at screening;\n4. A large hemispheric infarction defined as: lesion volume of 80 to 160 cm3 on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP).\n5. The time from onset to treatment must be ≤ 10 hours; if the onset time is unknown, treatment must be initiated within 10 hours after the time last known normal.\n\nExclusion Criteria:\n\n1. Theparticipant is likely to withdraw the supportive treatment on the first day;\n2. There is evidence indicating a concurrent infarction in the contralateral hemisphere sufficiently serious to affect functional outcome.\n3. There are clinical signs of brain herniation; CT\u002FMRI indicates a midline shift of \\>2 mm; CT\u002FMRI indicates cerebral hemorrhage;","80 Years",{"count":136,"type":21},725,[24,25],"The study is being conducted to evaluate the efficacy, and safety of HRS8179 injection in preventing and treating severe cerebral edema after large area cerebral infarction in the cerebral hemisphere",[140],"Severe Cerebral Edema Following Large Hemispheric Infarction","2025-08-18",{"date":143,"type":33},"2025-08-22",{"date":145,"type":33},"2025-02-07",{"date":147,"type":21},"2027-09",{"name":39,"class":40},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":16,"minAge":156,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":41},"100603230","phase-2-evaluate-the-long-term-efficacy-and-safety-of-shr-1918-in-patients-with-homozygous-familial-hypercholesterolemia-100603230","NCT07133815","Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia","A Multicenter, Single Arm, Open Label Phase II Clinical Study Evaluating the Long-term Efficacy and Safety of SHR-1918 in Homozygous Familial Hypercholesterolemia Patients","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent\n2. Subjects who received and completed the SHR-1918-301 study treatment in previous studies and were deemed to have therapeutic benefits by the researchers\n\nExclusion Criteria:\n\n1. Known to be allergic to the investigational drug or any component of the investigational drug, or to have experienced severe allergic reactions to other antibody drugs;\n2. History of malignant tumors in the past 5 years;\n3. There are serious concurrent diseases\n4. Pregnant or lactating women;\n5. The researchers determined that the subjects had poor compliance or any inappropriate factors for participating in this trial","12 Years",{"count":158,"type":21},55,[24],"A multicenter, single arm, open label phase II clinical study evaluating the long-term efficacy and safety of SHR-1918 in homozygous familial hypercholesterolemia patients",[162],"Homozygous Familial Hypercholesterolemia","2025-08-14",{"date":165,"type":33},"2025-08-21",{"date":167,"type":21},"2025-08",{"date":169,"type":21},"2027-12",{"name":39,"class":40},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":68,"sex":16,"minAge":17,"maxAge":69,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":41},"100585665","phase-1-a-single-ascending-dose-of-hrs-4029-in-healthy-subjects-100585665","NCT06905314","A Single Ascending Dose of HRS-4029 in Healthy Subjects","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HRS-4029 Following a Single Dose in Healthy Subjects","Inclusion Criteria:\n\n1. Age between 18 to 55 years.\n2. Body mass index (BMI) of 19.0 to 28.0 kg\u002Fm2 (inclusive).\n3. Agreed to take effective contraceptive measures during and 3 months after the last dose of the study period.\n4. Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written informed consent form (ICF).\n\nExclusion Criteria:\n\n1. Diseases with abnormal clinical manifestations that occurred before screening or are currently occurring and need to be excluded.\n2. Vital signs, physical examination, 12-lead electrocardiogram,or laboratory examination deemed clinically significant by the investigator .\n3. Subjects with positive tests for infectious diseases.\n4. Female who are pregnant or breastfeeding.\n5. Unable to tolerate venipunctures or have a history of fainting needles and blood.\n6. Historic abuse of alcoholic beverages\n7. Smoke ≥5 cigarettes per day within 3 months prior to the study\n8. History of drug abuse.\n9. Other reasons that the investigator consider it inappropriate to participate in the trial.",{"count":158,"type":21},[73],"The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.",[182],"Acute Ischemic Stroke","2025-03-25",{"date":185,"type":33},"2025-04-01",{"date":187,"type":21},"2025-04",{"date":189,"type":21},"2025-12",{"name":39,"class":40},""]